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Key Points
• The COX inhibitor in-
domethacin delays pro-
gression of ALL in
a human xenograft
mouse model.
• The xenograft-derived
ALL cells treated with
indomethacin express
elevated levels of p53.
Acute lymphoblastic leukemia (ALL) develops in the bonemarrow in the vicinity of stromal
cells known to promote tumor development and treatment resistance. We previously
showed that the cyclooxygenase (COX) inhibitor indomethacin prevents the ability of
stromal cells to diminish p53-mediated killing of cocultured ALL cells in vitro, possibly by
blocking the production of prostaglandin E2 (PGE2). Here, we propose that PGE2 released
by bone marrow stromal cells might be a target for improved treatment of pediatric ALL.
We used a xenograft model of human primary ALL cells in nonobese diabetic-scid
IL2rgnull mice to show that indomethacin delivered in the drinking water delayed the
progression of ALL in vivo. The progression was monitored by noninvasive in vivo
imaging of the engrafted leukemic cells, as well as by analyses of CD191CD101 leukemic
blasts present in spleen or bone marrow at the termination of the experiments. The
indomethacin treatment increased the level of p53 in the leukemic cells, implying that
COX inhibition might reduce progression of ALL by attenuating protective paracrine
PGE2 signaling from bone marrow stroma to leukemic cells.
Introduction
B-cell precursor acute lymphoblastic leukemia (ALL) is the most prevalent pediatric cancer.1
Because of improved multimodal chemotherapy regimens over the past decades, the general
survival of pediatric ALL is now close to 90%. There are, however, subgroups with poor prognosis,
and ALL is still 1 of the most common causes of cancer-related deaths in children.2 Furthermore,
pediatric ALL survivors often suffer from severe long-term side effects of the harsh chemotherapy
treatments.3 For these reasons, there is a steady search for new strategies to improve the treatment
of this disease.
The gene product of TP53 is regarded as an important barrier against cancer development,4 as well as
being imperative for successful cancer treatment.5,6 The tumor suppressor p53 is a key factor in DNA
damage responses, and it exerts most of its effect as a transcription factor.7 Accordingly, it is
presumed that progression of cancer involves restraining the function of p53, either by mutations
resulting in reduced stability of the protein, or by inactivating mutations.8 Although the majority of
pediatric cases of ALLs express wildtype p53 at the time of diagnosis,9-11 gain-of-function mutations
in the E3 ligase HDM2 that promotes degradation of p53 are frequent.12 Still, it is reasonable to assume
that progression of ALLs might also involve additional ways of mitigating the levels and functions of wild-
type TP53.
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We have previously shown that activation of the cyclic adenosine
monophosphate (cAMP)/PKA pathway in ALL cells promotes
degradation of p53 at the protein level via enforced interaction
between p53 and HDM2, resulting in reduced DNA damage–
mediated killing of the cells.13-15 ALL is derived from various
stages of immature B-cell precursors in the bone marrow,16 and
the disease develops in close contact with stromal cells in bone
marrow niches.17,18 Increasing evidence suggests that bone
marrow stromal cells are recruited to tumor sites where they can
contribute to tumor development, immunomodulation, and to
treatment resistance.19,20 We demonstrated that stromal cells,
when cocultured with patient-derived ALL cells, mimic the effects
of cAMP/PKA-stimulating factors such as forskolin and 8-CPT-
cAMP. Thus, both DNA damage-induced p53 and apoptosis
were reduced in the leukemic cells cocultured with bone marrow
stromal cells. Interestingly, the cyclooxygenase (COX) inhibitor
indomethacin added to the cocultures attenuated the protective
effect of the stromal cells. COX is 1 of the enzymes in the
cascade responsible for converting arachidonic acid to eicosa-
noids such as prostaglandins.21 We22 and others23 have shown
that bone marrow stromal cells produce prostaglandin E2
(PGE2), suggesting that the protecting effects of the bone
marrow stroma on DNA damage-induced killing of ALL cells may
involve PGE2.
Here we present COX as a putative target for improved
treatment of ALL by demonstrating the ability of indomethacin
to delay the progression of ALL in a xenograft model of primary
patient-derived ALL cells in nonobese diabetic-scid IL2rgnull
(NSG) mice.
Materials and methods
Cell culture and primary cell isolation
The ALL cell line REH24 was cultured as previously described.25
REH cells were originally derived from a 15-year-old female, and the
cytogenetics of the cells is t12;21.24 HEK293T26 cells were
cultured in Dulbecco’s modified Eagle medium/F-12-Glutamax
(Thermo Fisher, Waltham, MA) supplemented with 10% fetal
bovine serum (FBS), 125 U/mL penicillin, and 125 mg/mL
streptomycin. The HEK293T cells were subcultured every 2 to
3 days upon reaching 70% to 90% confluence. Primary ALL blasts
from newly diagnosed children were isolated as previously de-
scribed,13 and the number of cells isolated from each patient varied
substantially. The samples included in this study were selected
based on whether sufficient numbers of cells were available for
establishing the xenografts. Characteristics of the ALL cells
from each patient included in this study are presented in Table 1.
The collection of bone marrow aspirates was performed after
informed consent by parents, in accordance with the Declara-
tion of Helsinki. The collection of material was approved by the
Regional Ethics Committee of Norway region Sør-Øst C (REK
2014/883).
Lentivirus production in HEK293T cells
Lentiviral vectors containing genes coding for firefly luciferase and
enhanced green fluorescent protein (EGFP) were produced by
transfecting HEK293T with 8.3 mg of each of the plasmids:
pMD2.G envelope plasmid, pCMVD8.91 packaging plasmid, and
pSLIEW transfer plasmid.27 Cells were cultured to 70% to 90%
confluence at the day of transfection. The cell culture media was
changed approximately 1 hour before transfection. Transfection
mixtures were prepared using the Calcium Phosphate Transfection
Kit (Invitrogen, Carlsbad, CA) according to manufacturer’s instruc-
tions. Cell culture medium was changed 4 hours after transfection.
Viral supernatants were collected after 2 days and concentrated
using LentiX Concentrator (Takara Bio Inc., Kusatsu, Japan) at 4°C
overnight, before the viruses were collected by centrifugation at
1500g for 45 minutes at 4°C. Pellets were suspended in a small
volume (,1 mL) of cell culture medium and stored at 280°C.
Frozen lentiviral stocks were titrated using REH cells by using the
standard transduction protocol (see the following section).
Lentiviral transduction of ALL cells
Cells (5 3 105 cells per well) were seeded into 48-well plates with
4 mg/mL polybrene (Merck Millipore, Burlington, MA) present in the
cell culture media. REH cells were seeded in RPMI1640 medium
(Lonza, Basel, Switzerland) supplemented with 10% FBS and
125 U/mL penicillin and 125 mg/mL streptomycin, whereas
patient-derived ALL cells were seeded in SFEM medium (Stem
Cell Technologies, Vancouver, Canada) supplemented with
10% FBS, 20 ng/mL interleukin-3, and 10 ng/mL interleukin-7
(R&D Systems, Minneapolis, MN). Lentiviral concentrates
were added to the cells, and spinfection was performed by
centrifugating the plates at 900g for 50 minutes at 34°C. After
spinfection, plates were transferred to a standard cell in-
cubator (37°C, 5% CO2 in a humidified atmosphere) for 2 days
before removing the viral particles by 2 repeated washes at 300g
for 10 minutes at 4°C. A small aliquot was taken from these cells
to analyze the amount of EGFP1 cells by flow cytometry. The
remaining cells were subjected to intratibial (IT) injection into
NSG mice.
Establishment of xenograft model
Transduced ALL cells (5 3 105) were injected into 6- to 8-week-
old female NSG mice (The Jackson Laboratory, Bar Harbor, ME)
anesthetized with isoflurane (induction; 4% to 5%, maintenance;
2% to 3%, oxygen flow; 300 mL/min). The proximal end of the tibia
was exposed as the knee was kept in a flexed position. A 23G
needle was used to drill a hole into the tibia before injecting the
ALL cells (40 mL per animal) using a 31G insulin syringe. Mice
were treated with general and local analgesia; 0.05 mg/kg
Temgesic (Schlering-Plough, Kenilworth, NJ) and 1 to 2 mg/kg
Marcain (AstraZeneca, Cambridge, United Kingdom) before IT
injection. General analgesia treatments were repeated 6 to
8 hours after IT injection. Mice were treated with vehicle (0.05%
dimethyl sulfoxide) or 7.5 mg/mL indomethacin (Sigma-Aldrich,
St. Louis, MO) in the drinking water, with water changes every
second day throughout the entire experiment, as indicated in
the figures. Mice were housed under specific pathogenic-free
conditions with food and water ad libitum. Health status was
monitored daily, and all animal procedures were conducted
Table 1. Characteristics of patient-derived ALL cells
ALL#18 ALL#20 ALL#32
Age, y.mo 7.5 7.4 4.5
Sex Male Male Male
Cytogenetics t(12;21) t(1;19) Trisomy 21
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according to the approval by the Norwegian Food Safety Authority
under identification numbers 6626 and 16180.
In vivo imaging
Leukemic progression was monitored by noninvasive in vivo imaging
using an IVIS Spectrum CT instrument (PerkinElmer, Waltham, MA).
D-Luciferin (150 mg/kg, PerkinElmer) substrate was adminis-
tered by intraperitoneal injection. After 9 minutes, 3 images were
recorded with 1-minute intervals using the autoexposure setting.
Mice were euthanized when showing heavy engraftment or
symptoms above a predetermined humane end point.
Harvesting of splenocytes and bone marrow cells
At the end of experiments, spleens were harvested from the mice,
pictures taken, and cells were isolated from the spleens by crushing
them between 2 microscopic slides. Bone marrow was flushed
from the femur and tibia of the mice. For estimation of percentage
leukemic cells in the spleen or bone marrow samples, the cells
were stained with antibodies against human CD19 (#348814, BD
Biosciences, San Jose, CA) and CD10 (#312218, BioLegend,
San Diego, CA).
Measurement of serum PGE2
At the end of experiments, blood was collected from mice by
cardiac puncture, drained into regular microcentrifuge tubes, and
incubated for 30 minutes at room temperature. After centrifuga-
tion at 14 000g for 5 minutes at 4°C, the supernatants containing
serum were collected and stored at280°C until further use. PGE2
was measured using the Prostaglandin E2 ELISA kit – Monoclonal
(Cayman Chemical, Ann Arbor, MI) according to the manufac-
turer’s protocol.
Western immunoblot analysis of p53
Bone marrow cells or splenocytes collected from NSG mice were
lysed in radioimmunoprecipitation assay buffer (150 mM NaCl, 1%
Igepal CA-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 50 mM Tris, pH 8.0) for 20 minutes on ice, vortexing every
5 minutes. Supernatants were collected by centrifugation at
13 000g for 20 minutes at 4°C, and the protein concentration in
the lysates was measured using the Pierce BCA Protein Assay Kit
(ThermoFisher). Equal amounts of protein were loaded on a 4% to
20% Criterion TGX Precast Midi Protein Gel (Bio-Rad, Hercules,
CA), and western immunoblot analysis was performed using
Trans-Blot Turbo Midi PVDF Transfer Packs (Bio-Rad). Mem-
branes were blocked in 5% dry milk for 1 hour before probing with
the p53 DO-I antibody (1 mg/mL, #sc-126, Santa Cruz Bio-
technology, Dallas, TX) or Calnexin (1:1000, #2433S, Cell
Signaling Technology, Danvers, MA) at 4°C overnight. After 3 3
5 minutes washing in TBS with Tween 20, the membranes were
incubated in secondary antibody goat anti-rabbit IgG-HRP
(Bio-Rad #1706515) or goat anti-mouse IgG-HRP (Bio-Rad
#1706516) for 45 minutes at room temperature, followed by
3 3 5 minutes washing in TBS with Tween 20. The membranes
were exposed to the SuperSignal West Dura Extended Duration
Substrate kit (ThermoFisher) according to the manufacturer’s
protocol. Images were captured using a Syngene ChemiGenious
camera and presented by the GeneSnap software tool (Syngene,
Cambridge, United Kingdom). Intensity of protein bands was
quantified using the GeneTool software (Syngene).
Statistical methods
All statistical analyses were performed using the GraphPad Prism 8
software (San Diego, CA). Tests for normality were performed using
the Kolmogorov-Smirnov and Shapiro-Wilk tests. All datasets were
found to be normally distributed, and the unpaired Student t test
was therefore used to determine statistically significant differences
between treatment groups. P , .05 was considered as statistically
significant.
Results
Establishment of ALL xenografts in NSG mice
ALL-derived REH cells, or primary leukemic cells isolated from
bone marrow aspirates of children diagnosed with ALL, were
stably transfected with the firefly luciferase-EGFP vector by
lentiviral transduction. The transfection efficiency varied, but was
typically between 2% and 10% for primary patient-derived cells,
whereas it was ;90% for REH cells, as monitored by EGFP
expression (Figure 1A). ALL cells were IT injected in NSGmice, and
we followed the progression of ALL in the mice by noninvasive
in vivo imaging of luminescence from the firefly luciferase expressed
in the leukemic cells. As shown in Figure 1B, growth of leukemic
cells from ALL#18 was notable 11 weeks after injecting the ALL
cells, and the leukemia progressed for another 4 weeks until the
animals were euthanized. It should be emphasized, however, that
the kinetics of the leukemia progression varied between the
different primary ALL donors (data not shown). All experiments
were terminated when the animals displayed symptoms beyond
a predetermined humane end point. After terminating the exper-
iment presented in Figure 1B, cells were isolated from the bone
marrow of the mice, and the percentage of CD191CD101 leukemic
cells was monitored by flow cytometry analyses (Figure 1C, left). As
shown in the right panel of Figure 1C, engraftment of ALL#18
increased the percentage of human CD191CD101 in the murine
bone marrow by 91%, compared with bone marrow cells from
healthy control mice. Furthermore, spleens were harvested and
spleen weights recorded (Figure 1D, left). The right panel of
Figure 1D shows that engraftment of ALL#18 increased the
weight of the spleens by 81% compared with spleens from healthy
control mice.
Indomethacin reduces the serum levels of PGE2 in
NSG mice
Using in vitro models, we previously showed that ALL cells are
exposed to PGE2 from bone marrow–derived stromal cells, and that
PGE2 in turn lowers the levels of DNA damage-induced p53 and
apoptosis in the ALL cells.22 Based on the ability of indomethacin to
counteract the effects of stromal cells on cocultured ALL cells,22
we proposed that indomethacin might also counteract the effects of
PGE2 in vivo. Before assessing the effects of indomethacin on ALL
progression in NSG mice, we ensured that indomethacin indeed
reduced the serum levels of PGE2 in vivo. Thus, indomethacin or
vehicle was provided in the drinking water to NSG mice, and the
levels of PGE2 were monitored after 10 weeks. As shown in
Figure 2, indomethacin reduced the PGE2 levels in serum by 80%.
Indomethacin delays the progression of REH in vivo
REH cells transduced with the firefly luciferase-EGFP vector were
injected into NSG mice. Indomethacin or vehicle was administered
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Figure 1. Establishment of xenograft model of ALL in NSG mice. (A) Lentiviral transduction efficiency of the pSLIEW vector into ALL#18, ALL#20, and REH cells was
measured by flow cytometry analyses of EGFP fluorescence. (B-D) Four mice were IT injected with transduced ALL#18. (B) Progression of xenograft ALL#18 was followed by
detection of luminescence intensity using noninvasive in vivo imaging, starting at 11 weeks after IT injection. (C) End point flow cytometry analysis of CD191CD101 leukemic
cells in the bone marrow of xenograft ALL#18 mice. (Left) Dot plot presentation of CD19 vs CD10 expression of bone marrow cells from the mouse shown in panel B. (Right)
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in the drinking water every second day throughout the entire
experiment, and the growth of the cancer cells was followed by
noninvasive in vivo imaging from 1 week after IT injection. As
shown in Figure 3A-B, the luminescence from the leukemic cells
treated with indomethacin was reduced by 81% 3 weeks after
initiating the experiment. At 4 weeks after IT injection, the reduced
growth of indomethacin-treated REH cells persisted, whereas the
growth of REH cells in mice exposed to vehicle substantially
increased.
Indomethacin delays the progression of primary ALL
in vivo
Leukemic blasts from ALL#18 were transfected with the firefly
luciferase-EGFP vector, and the ALL cells were injected into NSG
mice. Indomethacin or vehicle was administered in the drinking
water, and the progression of the leukemia was followed by
noninvasive in vivo imaging of the mice. The images taken at the end
of the experiment at day 72 (Figure 4A) indicated that indomethacin
treatment of the mice reduced the progression of ALL#18. The
mice were euthanized, and the percentage of leukemic cells in
various organs was assessed by flow cytometry. Indomethacin was
found to reduce the load of CD191CD101 cells in the bone
marrow (Figure 4B, left) and spleen (Figure 4B, right) by 31% and
37%, respectively. The weights of the spleens were also reduced by
indomethacin (Figure 4C), further supporting the inhibitory effect of
COX inhibition on progression of ALL#18 in vivo. Finally, we
collected spleens from xenografts of ALL#20 and #32 treated with
indomethacin or vehicle, and again indomethacin reduced the load
of leukemic blasts by 42% (ALL#20, Figure 4D) and 34% (ALL#32,
Figure 4E). In supplemental Table 1, we have summarized the data
for all the xenografts included in the study.
Indomethacin enhances the levels of p53 in cells from
bone marrow of xenograft mice
We previously proposed that PGE2 reduces DNA damage-induced
apoptosis in cultured ALL cells by diminishing the p53 levels.22 To
test our hypothesis that indomethacin exerts its inhibiting effect on
leukemia progression by counteracting the stroma cell–mediated
downregulation of p53, we performed western immunoblot
analyses of p53 levels in cells collected from bone marrow
samples of mice treated with or without indomethacin. We used
antibodies specific for human p53 and the human control protein
calnexin, ensuring that only p53 levels in the leukemic cells were
monitored. Irradiated REH cells were included as a positive control
for human p53 in the immunoblot presented in Figure 5 (left). As
shown in the right panel of Figure 5A, indomethacin significantly
enhanced the levels of p53 in the bone marrow cells of xenograft
REH mice by 27%. Similar analyses of p53 expression in bone
marrow cells from xenograft ALL#18 and xenograft ALL#20 mice
revealed the p53 expression was enhanced by 46% (Figure 5B)
and 71% (Figure 5C), respectively.
Discussion
In the present study, we have used a xenograft model of ALL in
NSGmice to show that the COX inhibitor indomethacin delays the
progression of ALL in vivo. By injecting primary ALL blasts or
the ALL-derived cell line, REH, directly into the bone marrow of the
mice, the engrafted human leukemic cells were exposed to factors
produced by resident stromal cells. The xenograft model allowed
us to follow the progression of ALL in vivo, and to monitor the
impact of targeting bone marrow–derived components.
Our previous in vitro studies revealed that elevation of cAMP levels
in ALL cells increases the survival of the cells by reducing p53
accumulation. This was achieved either by exposing the ALL cells
to cAMP elevating compounds such as forskolin and 8-CPT-
cAMP13-15 or by coculturing the ALL cells with bone marrow–
derived stromal cells.22 We22 and others23 have shown that bone
marrow stromal cells produce PGE2, which upon binding to its
receptors, is able to elicit a cAMP response in the target cells.28,29
ALL cells are known to express the EP2 type of PGE2
receptors,19,20 and we showed that indomethacin countered the
protective effects of stromal cells on the cocultured leukemic
blasts. Thus, we proposed that the enhanced survival of leukemic
cells was provided by PGE2 produced by the bone marrow
stromal cells.22
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID)
used for more than half a decade to treat symptoms of inflammation
such as fever, pain, and stiffness.30 Based on our previous in vitro
experiments,13-15,22 we proposed that indomethacin might be used
in treatment of ALL. To test our hypothesis in vivo, we exposed the
ALL xenograft mice to daily doses of indomethacin that were
lower than the anti-inflammatory dosages commonly used in mice
studies.31-33 As expected, we demonstrated that indomethacin
Figure 1. (continued) The percentage of human CD191CD101 leukemic cells within the total bone marrow cell population of xenograft ALL#18 mice compared with
noninjected (control) mice. Each circle represents the percentage of CD191CD101 cells in the bone marrow of 1 mouse. Horizontal lines represent the mean of each
treatment group, *P , .01 (unpaired Student t test). (D, left) Spleens from 4 xenograft ALL#18 mice and from 1 noninjected (control) mouse. (Right) Weight of spleens from
the 4 xenograft mice compared with spleens from 4 control mice. Each circle represents the spleen weight (g) of 1 mouse. Horizontal lines represent the mean of each
treatment group, *P , .01 (unpaired Student t test).
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Figure 2. Indomethacin reduces the level of PGE2 in mouse serum. Serum
PGE2 measurement from serum of mice treated with and without indomethacin in
their drinking water as described in “Materials and methods." Each circle represents
the concentration of PGE2 (pg/mL) in the serum from 1 mouse. Horizontal lines
represent the mean of each treatment group, *P , .01 (unpaired Student t test).
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reduced the serum levels of PGE2 in the xenograft mice by;80%.
Furthermore, indomethacin significantly delayed the growth of the
ALL xenografts of both primary leukemic blasts and the ALL-
derived cell line REH. It is believed that early oncogenic events
provide premalignant cells with slightly elevated levels of p53 as
a guardian against further DNA damage-induced cancer de-
velopment.34 Our previous finding that bone marrow–derived
stromal cells reduce the levels of both basal and DNA damage-
induced p53 in ALL cells22 implied that that bone marrow stromal
cells might contribute to tumor progression by attenuating the p53
levels in the leukemic blasts. In support of this perception, we
show here that indomethacin enhanced the levels of p53 in the
leukemic cells isolated from the bone marrow of xenograft mice.
We therefore propose that indomethacin delays the progression
of ALL in the present xenograft model by countering the ability of
bone marrow stroma to reduce the levels of p53.
The current favorable prognosis for children with ALL is based
on successful development of multimodal chemotherapy.35 The
backside of the coin is that these children often suffer from long-
term side effects of the harsh treatment.36 Enhancement of the
therapeutic index of current chemotherapeutic drugs is there-
fore highly desired. This would potentially allow lowering the
effective doses of the drugs, and thereby reduce the devastating
side effects of the treatments. Considering the critical role of p53
in DNA damage-based chemotherapy,37,38 we propose here
that indomethacin may be useful as an adjuvant to increase
the therapeutic index of DNA-damaging drugs. This notion is
supported by our previous results showing that bone marrow
stromal cells reduce DNA damage-induced p53 and apoptosis
of ALL cells, and that indomethacin enhances DNA damage-
induced apoptosis of leukemic cells cocultured with bone marrow
stroma cells.22 However, although indomethacin is a widely used
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Figure 3. Indomethacin delays progression of REH in vivo. Xenograft REH mice (5 mice per treatment group) were treated with indomethacin or vehicle as described in
“Materials and methods." (A) Progression of leukemia was followed by noninvasive in vivo imaging of luminescence from the mice. The images were taken between 1 and
4 weeks after IT injection as indicated. (B) Xenograft luciferase activity (photons per second [p/s]) from the xenografts presented in panel A measured relative to week 1 after
IT injection. Data represent the mean 6 standard error of the mean, n 5 5, *P , .05 (unpaired Student t test).
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NSAID, its side effects after long-term use should not be
neglected.30 One might therefore also consider alternative
approaches to target the cAMP signaling pathway in leukemic
cells. This could include protein kinase A inhibitors such as Rp-
8-Br-cAMPs, or specific inhibitors of the functional EP2 (PGE2)
receptors known to be expressed on ALL cells.19,20 Interestingly,
it was previously shown that inhibiting adenylyl cyclase by the
opioid DL-methadone enhanced the sensitivity of ALL cells to
doxorubicin.39
NSAIDs have been proposed to reduce the risk of developing solid
cancers.40,41 Although the antitumor effects of indomethacin co-
lorectal cancers are documented,42,43 the mechanisms of action are
not established. The role of indomethacin as an unselective COX
inhibitor is clear, but COX-independent effects of indomethacin have
also been documented, such as activation of the peroxisome
proliferator-activated receptors g and d.44,45 It should also be
noted that PGE2 might exert its known antiapoptotic effects via
mechanisms other than enhancing cAMP levels, including acting via
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Figure 4. Indomethacin delays progression of ALL
in vivo. (A) Xenograft ALL#18 mice (5 mice per
treatment group) were treated with indomethacin or
vehicle as described in “Materials and methods." Pro-
gression of leukemia was followed by noninvasive in vivo
imaging of luminescence from the mice. The images were
taken 10 weeks after IT injection. (B) End point flow
cytometry analysis of human CD191CD101 leukemic
cells in the total bone marrow (left) and spleen (right) cell
populations of the mice presented in panel A. Each circle
represents the percentage of human CD191CD101 cells
in the total spleen or bone marrow cell populations of 1
mouse. Horizontal lines represent the mean of each
treatment group, *P , .05 (unpaired Student t test). (C)
Weight of spleens from the mice presented in panel A.
Each circle represents the spleen weight (g) of 1 mouse.
Horizontal lines represent the mean of each treatment
group, *P 5 .05 (unpaired Student t test). (D-E) End point
flow cytometry analysis of CD191CD101 leukemic cells
in the bone marrow of xenograft ALL#20 (D) and
ALL#32 (E) mice. Each circle represents the percentage
of human CD191CD101 cells in the total bone marrow
cell population of 1 mouse. Horizontal lines represent the
mean of each treatment group, *P , .05, **P , .01
(unpaired Student t test).
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the EGFR,46,47 phosphatidylinositol 3-kinase/AKT,48 and extracellular
signal-regulated kinase49 pathways.We therefore cannot exclude the
possibility that indomethacin prevents the growth of ALL xenograft by
mechanisms other than via targeting PGE2-induced cAMP signaling.
Nevertheless, the novel findings of the present study remain: that
a commonly used NSAID such as indomethacin can enhance the
level of p53 in leukemic cells and delay the progression of ALL in vivo.
Our results imply that targeting the cAMP signaling pathway might be
useful to increase the therapeutic index of DNA-damaging drugs, and
thereby potentially reduce the long-term side effects of current
antileukemia treatment regimens.
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